Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Current Assets (2020 - 2025)

Mirum Pharmaceuticals has reported Current Assets over the past 6 years, most recently at $549.7 million for Q4 2025.

  • Quarterly results put Current Assets at $549.7 million for Q4 2025, up 39.94% from a year ago — trailing twelve months through Dec 2025 was $549.7 million (up 39.94% YoY), and the annual figure for FY2025 was $549.7 million, up 39.94%.
  • Current Assets for Q4 2025 was $549.7 million at Mirum Pharmaceuticals, up from $530.6 million in the prior quarter.
  • Over the last five years, Current Assets for MIRM hit a ceiling of $549.7 million in Q4 2025 and a floor of $147.2 million in Q2 2022.
  • Median Current Assets over the past 5 years was $375.7 million (2023), compared with a mean of $316.5 million.
  • Biggest five-year swings in Current Assets: plummeted 35.52% in 2022 and later surged 160.46% in 2023.
  • Mirum Pharmaceuticals' Current Assets stood at $166.6 million in 2021, then rose by 14.19% to $190.2 million in 2022, then soared by 103.73% to $387.5 million in 2023, then grew by 1.35% to $392.8 million in 2024, then surged by 39.94% to $549.7 million in 2025.
  • The last three reported values for Current Assets were $549.7 million (Q4 2025), $530.6 million (Q3 2025), and $453.4 million (Q2 2025) per Business Quant data.